Physician profile
Noah Gilson
NPI 1821054230
$3,581.47
in general payments reported to CMS, 2019-2025
40 companies · $55.11 in 2025
The $55.11 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,100 · 2020: $336 · 2021: $544 · 2022: $708 · 2023: $771 · 2024: $66.51 · 2025: $55.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $893.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $892.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $722.05 | 2019-2023 | |
| Abbvie INC. | $291.00 | 2021-2023 | |
| Ucb, INC. | $266.17 | 2019-2023 | Briviact |
| Jazz Pharmaceuticals INC. | $222.36 | 2019-2023 | Xywav |
| Amneal Pharmaceuticals LLC | $213.12 | 2019-2023 | Rytary |
| Biogen, INC. | $201.50 | 2019-2023 | Vumerity, Tysabri |
| Pfizer INC. | $194.96 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $129.46 | 2022 | |
| Eisai INC. | $106.94 | 2019-2023 | |
| Amgen INC. | $102.62 | 2019-2022 | |
| Argenx US, INC. | $101.50 | 2022-2023 | Vyvgart Hytrulo, Vyvgart |
| Genentech USA, INC. | $100.17 | 2019-2023 | Ocrevus, Enspryng |
| Tanabe Pharma America, INC. | $86.96 | 2019-2022 | |
| Lundbeck LLC | $80.16 | 2021-2023 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $75.90 | 2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $71.62 | 2019 | |
| Harmony Biosciences LLC | $66.73 | 2020-2023 | Wakix |
| Alexion Pharmaceuticals, INC. | $59.17 | 2019 | |
| Adamas Pharmaceuticals, INC. | $56.52 | 2019-2020 | |
| Genzyme Corporation | $55.81 | 2019 | |
| Inspire Medical Systems, INC. | $48.07 | 2023 | Inspire |
| Sunovion Pharmaceuticals INC. | $43.64 | 2019-2020 | |
| Sk Life Science, INC. | $40.85 | 2023 | |
| Neurocrine Biosciences, INC. | $29.06 | 2023 | Ingrezza, Ongentys |
| Mdd US Operations, LLC | $29.00 | 2020 | |
| Janssen Pharmaceuticals, INC | $27.35 | 2022 | |
| Zyla Life Sciences, INC. | $24.36 | 2019 | |
| Greenwich Biosciences, INC. | $17.95 | 2019 | |
| Impel Pharmaceuticals INC. | $17.25 | 2022 | |
| Amylyx Pharmaceuticals, INC. | $16.71 | 2023 | Relyvrio |
| Collegium Pharmaceutical, INC. | $14.87 | 2022 | |
| Acadia Pharmaceuticals INC | $14.51 | 2019 | |
| Promius Pharma LLC | $14.08 | 2019 | |
| Lilly USA, LLC | $14.04 | 2019 | |
| Assertio Therapeutics, INC. | $13.10 | 2020 | |
| Neurelis, INC. | $11.91 | 2022 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noah Gilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.